Clearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder

Core Viewpoint - Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center as a clinical site, following the enrollment of the first patient [1][3]. Group 1: Clinical Trial Expansion - The addition of Tel Aviv Sourasky Medical Center, led by Dr. David Zeltser, enhances the trial's capacity to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile [2]. - Other prestigious institutions involved in the trial include Yale School of Medicine and Johns Hopkins University, indicating a strong clinical network [2][3]. Group 2: Company Objectives and Focus - Clearmind is focused on developing novel psychedelic-derived therapeutics to address major under-treated health issues, particularly AUD, which affects millions and is responsible for 2.6 million deaths annually [3][4]. - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4]. Group 3: Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents to strengthen its position [5].